Clinical study on efficiency of fludarabine-based regimen for the patients with chronic lymphocytic leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 70-72, 2012.
Article
en Zh
| WPRIM
| ID: wpr-331019
Biblioteca responsable:
WPRO
ABSTRACT
The aim of this study was to evaluate the therapeutic effects and adverse reactions of fludarabine-based regimen for patients with chronic lymphocytic leukemia(CLL).18 patients with CLL were treated with F regimen [fludarabine 30 mg/(m(2)·d) intravenously for 3 d, repeatedly every 28 days]. 22 patients were treated with FC regimen [fludarabine 25 mg/(m(2)·d) plus cyclophosphamide 250 mg/(m(2)·d) intravenously for 3 d, repeatedly every 28 days]. The results showed that the rate of complete remission (CR), partial remission (PR) and overall remission (OR) reached 16.7%, 61.1% and 77.8% in the F regimen groups and 59.1%, 40.9% and 100% in the FC regimen groups (P < 0.05, P > 0.05 and P > 0.05), respectively. FC regimen resulted in significantly higher CR rate than that in single-agent fludarabine regimen. The main adverse reactions were myelosuppression and immunosuppression. No significant differences were found between the two regimens. FC regimen did not increase the rate of severe infections. It is concluded that FC regimen can give higher CR rate as compared with F regimen, fludarabine-based regimens is effective and safe first-line regimen for patients with CLL.
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Vidarabina
/
Leucemia Linfocítica Crónica de Células B
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Resultado del Tratamiento
/
Ciclofosfamida
/
Usos Terapéuticos
/
Quimioterapia
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Año:
2012
Tipo del documento:
Article